Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements

Inclusion Criteria: * Postoperative Total joint replacement with osteoarthritis as the underlying pathology * Proven non-infected symptomatic Total Joint Arthroplasty (TJA) (joint implanted for \>12 months post-op) * Age (50 to 85 years of age); based on a 10% trim of the age distribution for Summa Health System TJAs (7/1/08-6/30/2009). Exclusion Criteria: * An infection of any kind (prior to, or during the study) * Rheumatoid arthritis as the underlying pathology * Cortisone injection received \<6 months prior to study enrollment * Insulin dependent diabetes * Diagnosed immunodeficiency * On dialysis or have poor kidney function * Anti-coagulant medication (e.g., Coumadin or \>100mg of Aspirin daily) * Anti-seizure medication (e.g., Dilantin) * Steroidal medication (e.g., Prednisone, Advair or Symbicort) * NSAIDS (e.g., Celebrex or Toradol); a 14-day washout period will be allowed * bisphosphonates (e.g., Fosamax, Actonel, Aredia, Didronel, Boniva or Reclast) * hormonal therapy (e.g., Estrogen, Progesterone or Testosterone) * Cancer (active or in remission) * Planned concurrent vitamins exceeding a standard daily multivitamin or exceeding the Recommended Daily Allowance (RDA) for individual vitamins if used alone; a 72 hour wash out period will be allowed * A glucose-6-phosphate dehydrogenase (G6PD) deficiency * Pregnant or lactating; females who are in their reproductive years must have a negative serum pregnancy * Lactose intolerant * Citric acid intolerant